Arrowhead Pharmaceuticals’ investigational cystic fibrosis treatment candidate ARO-ENaC can effectively target the epithelial sodium channel alpha subunit (αENaC) in the lungs of rats, preclinical studies show. Given that ENaC is a well-known mediator of common cystic fibrosis symptoms, such as airway dehydration and mucus accumulation, these results suggest that ARO-ENaC may be a potential therapeutic […] The post #ATS2018 — Arrowhead’s Investigational CF Treatment ARO-ENaC Shows Potential in Preclinical Studies appeared first on Cystic Fibrosis News Today. | ||
|
lunes, 28 de mayo de 2018
#ATS2018 – Potential CF Therapy ARO-ENaC Shows Promise in Studies
#ATS2018 – Potential CF Therapy ARO-ENaC Shows Promise in Studies
![](https://blogger.googleusercontent.com/img/proxy/AVvXsEgPhRQZJMThxMp-e_oXL_1Qw6X9p3hTdOwZ8v4aofc8YKspWnUEllidlynchYPoVZ9-pCJ9Zg02zd95J6Ltm4Y09RQetfAVn70oG7ccqBSTQfwfty69Uxk6Q4AGDkZEczmEvKvAh0eMQ5ARA47YTPo71Y2FoIub1jE27njynOAxhkqdlB_Eq9V9I4qMBlDtrD5mkNUUXnzzMi2baB94slFWZNxfyLc_AA=s0-d-e1-ft)
![ARO-ENaC](https://blogger.googleusercontent.com/img/proxy/AVvXsEhyd0CVU0ZkU6oJWJPBlSo1mA16_zKudvVjeikQ-fwxi9525UFOIE3fY8LsNhcdWXEZVvSeJAzg-C0ZAIQ7uvLZReK0TpMiRBKRLolRa06XeGvs4qf-uNFwpgi6th-T4oHDjJlldgHz7kgcuBS4xfAPhNxGVMtyn8XmJiVlS5dCJ10SXobULMaFEH5vnsTCFgY1UlDI7BxnZYq-N3hQhLQ-P48=s0-d-e1-ft)
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario